Evaluation of an immunoassay (EMIT) for mycophenolic acid in plasma from renal transplant recipients compared with a high-performance liquid chromatography assay

Therapeutic Drug Monitoring

Volumn 20, Issue 6, 1998, Pages 685-690

  Beal, Joanne L ^a   Jones, Christopher E ^a   Taylor, Paul J ^a   Tett, Susan E ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

High performance liquid chromatography Renal transplant; Immunoassay; Immunosuppressant; Mycophenolic acid

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ANALYTIC METHOD; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG METABOLISM; DRUG MONITORING; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; KIDNEY TRANSPLANTATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SOLID PHASE EXTRACTION;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID;

EID: 0031786415     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199812000-00019     Document Type: Article

References (23)

1. Lipsky JJ. Mycophenolate mofetil. Lancet 1996;348:1357-9.
2. Langman LJ, LeGatt DF, Halloran PF, et al. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients. Transplantation 1996;62:666-72.
3. Bullingham R, Monroe S, Nicholls A, et al. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 1996;36:315-24.
4. Nowak I, Shaw LM. Effect of mycophenolic acid glucuronide on inosine monophosphate dehydrogenase activity. Ther Drug Monit 1997;19:358-60.
5. Bullingham R, Shah J, Goldblum R, et al. Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients. Br J Clin Pharmacol 1996; 41:513-6.
6. Zanker B, Schleibner S, Schneeberger H, et al. Mycophenolate mofetil in patients with acute renal failure: Evidence of metabolite (MPAG) accumulation and removal by dialysis. Transpl Int 1996; 9:S308-10.
7. Parker G, Bullingham R, Kamm B, et al. Pharmacokinetics of oral mycophenolate mofetil in volunteer subjects with varying degrees of hepatic oxidative impairment. J Clin Pharmacol 1996;36:332-44.
8. McDiarmid SV. Mycophenolate mofetil in liver transplantation. Clin Transplant 1996;10:140-5.
9. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996;61:1029-37.
10. Shaw LM, Nowak I, Mycophenolic acid: Measurement and relationship to pharmacologic effects. Ther Drug Monit 1995;17: 685-9.
11. Tsina I, Chu F, Hama K, et al. Manual and automated (robotic) high-performance liquid chromatography methods for the determination of mycophenolic acid and its glucuronide conjugate in human plasma. J Chromatogr B Biomed Appl 1996;675:119-29.
12. Jones CE, Taylor PJ, Johnson AG. High-performance liquid chromatographic determination of mycophenolic acid and its glucuronide metabolite in human plasma. J Chromatogr 1998;708:229-34.
13. Behring Diagnostics Inc., CA. EMIT Mycophenolic Acid Assay: Manufacturer's Guidelines 1996. Clin Chem 1997;43:S209.
14. Holt DW, Johnston A. Monitoring new immunosuppressive agents. Are the methods adequate? Drug Metab Drug Interact 1997;14:5-15.
15. Roche Diagnostic Systems, Inc. Basel, Switzerland: COBAS MIRA user's manual, 1991.
16. Shaw LM, Sollinger HW, Halloran P, et al. Mycophenolate mofetil: A report of the consensus panel. Ther Drug Monit 1995; 17:690-9.
17. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1: 307-10.
18. Shah VP, Midah KK, Dighe S, et al. Analytical methods validation: Bioavailability, bioequivalence, and pharmacokinetic studies. J Pharm Sci 1992;81:309-12.
19. Morris R, Tett S, Ray J. Cyclosporin-A monitoring in Australia: Consensus recommendations. Ther Drug Monit 1994;16:570-6.
20. Pawinski T, Jones K, Holt DW. Validation of Behring Diagnostics EMIT to measure mycophenolic acid in human plasma. Ther Drug Monit 1997;19:557.
21. Dias VC, Martens C, Zimmermann L, et al. Evaluation of the EMIT mycophenolic acid assay on the COBAS MIRA®. Ther Drug Monit 1997;19:563.
22. Filler G, Ehrich J. Mycophenolate mofetil for rescue therapy in acute renal transplant rejection in children should always be monitored by measurement of trough concentration. Nephrol Dial Transplant 1997;12:374-5.
23. Barre J, Simon N, Tillement JP. Mycophenolate mofetil, a new immunosuppressive agent. Is pharmacokinetic monitoring justified?. Therapie 1997;52:139-42.